Can I Take Reishi Mushroom with Spironolactone?

What Is Spironolactone and Why Is It Prescribed?

Spironolactone is a potassium-sparing diuretic and aldosterone antagonist first approved by the FDA in 1960. It blocks mineralocorticoid receptors in the kidney's collecting duct, reducing sodium retention and lowering blood pressure. At doses of 50 to 200 mg daily it also competitively antagonizes androgen receptors, which is why dermatologists and gynecologists prescribe it off-label for hormonal acne and hirsutism in women [1].

Hormonal Acne Use

For adults with treatment-resistant hormonal acne, spironolactone 100 mg/day reduced inflammatory lesion counts by roughly 50% at 12 weeks in a 2017 randomized controlled trial (N=410) published in the British Journal of Dermatology [2]. The Endocrine Society's 2018 guideline on polycystic ovary syndrome lists spironolactone as an acceptable second-line option for hyperandrogenic skin conditions when combined with oral contraceptives [3].

Pharmacokinetics Relevant to Interactions

After oral dosing, spironolactone is rapidly converted to two active metabolites: canrenone and 7-alpha-thiomethylspironolactone. Both are highly protein-bound (greater than 90%), primarily to albumin. That protein binding is one reason other protein-bound compounds, including some triterpene acids found in reishi, could theoretically compete at the same binding sites, though no human trial has confirmed displacement at clinically meaningful concentrations [4].

What Is Reishi Mushroom?

Reishi (Ganoderma lucidum) has been used in traditional East Asian medicine for over 2,000 years. Modern preparations standardize to two main bioactive classes: polysaccharides (particularly beta-glucans) and triterpene acids (ganoderic acids A through Z and beyond). These two chemical families produce different biological effects, and understanding them separately matters when you are evaluating interactions with a prescription drug [5].

Polysaccharides and Immune Modulation

Reishi's beta-glucans bind to dectin-1 receptors and toll-like receptor 2 on macrophages and natural killer cells, upregulating cytokine production. A 2006 randomized trial (N=68) found that Ganoderma polysaccharide extract increased natural killer cell activity and CD56 cell counts in healthy adults over 12 weeks [6]. This immune-activating effect is the reason reishi is marketed broadly as an "immune support" supplement.

Triterpene Acids and Antiplatelet Activity

Ganoderic acids are where the bleeding-related concerns originate. In platelet-rich plasma models, ganoderic acid S inhibited collagen-induced platelet aggregation with an IC50 of approximately 10 micromolar [7]. Separately, a 2012 study found that a standardized reishi extract prolonged activated partial thromboplastin time (aPTT) in male Wistar rats given 500 mg/kg for 28 days [8]. These are animal and in-vitro data, not human trials, but they form the mechanistic basis for caution.

The Spironolactone-Reishi Interaction: What the Evidence Actually Shows

No dedicated human pharmacokinetic or pharmacodynamic study has evaluated the spironolactone-reishi combination directly. The interaction concern is built from three separate lines of evidence, each worth examining on its own merits.

Line 1: Anticoagulant and Antiplatelet Potentiation

Spironolactone does not itself carry a major anticoagulant effect. However, at higher doses it can reduce synthesis of clotting factor proteins to a minor degree, and patients on spironolactone for heart failure are frequently co-prescribed warfarin or direct oral anticoagulants (DOACs). Reishi's ganoderic acids add an independent antiplatelet signal. If you are on spironolactone plus an anticoagulant plus reishi, the combination represents three overlapping inputs to the same hemostatic pathway. The Natural Medicines database classifies the reishi-anticoagulant interaction as "moderate" with a recommendation to monitor INR closely [9].

Line 2: CYP Enzyme Considerations

Spironolactone is metabolized partly by CYP3A4. Several ganoderic acids have shown inhibitory activity at CYP3A4 in hepatic microsome assays, though IC50 values in those assays (typically 50 to 100 micromolar) are well above concentrations achievable with standard supplement doses. The FDA's drug interaction guidance notes that in-vitro CYP inhibition data below a ratio of 0.1 (inhibitor concentration divided by IC50) are unlikely to produce clinically significant interactions in vivo [10]. At standard reishi doses, that threshold is probably not crossed, but concentrated reishi extracts at 4 g/day or more move the ratio closer to a range that warrants attention.

Line 3: Hormonal and Androgenic Cross-Talk

Reishi polysaccharides have shown 5-alpha-reductase inhibitory activity in cell-culture studies, meaning they may reduce conversion of testosterone to dihydrotestosterone (DHT) [11]. Spironolactone also reduces androgenic signaling, though through direct androgen-receptor blockade rather than 5-alpha-reductase inhibition. These two mechanisms are complementary rather than antagonistic. Some integrative dermatologists use that overlap intentionally, combining saw palmetto (another 5-alpha-reductase inhibitor) with low-dose spironolactone. Reishi is not saw palmetto, but the mechanistic overlap is worth noting: the acne benefit may theoretically be additive, while the hormonal effects on aldosterone receptors remain unstudied.

The HealthRX clinical team uses a three-tier risk classification for supplement combinations with spironolactone:

Tier 1 (avoid without prescriber approval): Supplements with strong anticoagulant evidence or potassium load above 300 mg per serving. Examples include high-dose fish oil (greater than 3 g EPA+DHA), dong quai, and potassium-fortified greens powders.

Tier 2 (use with monitoring, disclose to prescriber): Supplements with moderate antiplatelet evidence, CYP3A4 interaction potential, or immune-modulating beta-glucans at therapeutic doses. Reishi mushroom falls here.

Tier 3 (generally low concern, still disclose): Supplements with minimal pharmacodynamic overlap and no meaningful CYP activity at standard doses. Examples include magnesium glycinate, vitamin D3, and zinc picolinate.

Reishi sits in Tier 2. That means it is not a hard stop, but it does mean you should disclose it to your prescriber, stick to doses at or below 1 g/day of standardized extract, and have your potassium and CBC checked at your next routine visit.

Potassium: The Underappreciated Variable

Spironolactone's most clinically serious adverse effect is hyperkalemia. In the RALES trial (N=1,663), patients with severe heart failure taking spironolactone 25 mg/day had a 30% relative reduction in mortality, but also a 2% incidence of serious hyperkalemia [12]. For acne patients on 50 to 150 mg/day without renal impairment, the risk is lower, but routine potassium monitoring is still standard of care.

Does Reishi Contain Meaningful Potassium?

Dried reishi mushroom contains roughly 300 to 500 mg of potassium per 100 g of raw material. A 2 g capsule dose carries approximately 6 to 10 mg of elemental potassium, which is negligible. Whole-food reishi preparations or reishi-enriched protein powders, however, can deliver 50 to 100 mg per serving. That is not a pharmacologically dangerous amount on its own, but stacked against a high-potassium diet and spironolactone in a patient with reduced kidney function, it adds to the cumulative load.

Who Should Be Most Careful

Patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m squared are at the highest risk for potassium accumulation on spironolactone. The 2022 KDIGO guidelines recommend against spironolactone use when eGFR falls below 30 mL/min/1.73 m squared [13]. If you fall into the eGFR 30 to 60 range and want to add reishi, that conversation with your nephrologist or prescriber is non-optional.

Immune Modulation: Relevant for Specific Populations

Spironolactone carries a mild immunosuppressive signal at high doses through its glucocorticoid-receptor partial agonism. Reishi's beta-glucans push in the opposite direction, stimulating innate immune activity. In healthy adults, that opposition is unlikely to produce a clinically relevant problem.

Autoimmune Conditions

Patients on spironolactone for conditions that intersect with autoimmune activity, such as lupus-associated hypertension or adrenal-related conditions, should be cautious. Reishi's immune-activating properties could theoretically worsen disease activity in a lupus-like flare. A 2020 review in the Journal of Ethnopharmacology noted that beta-glucan supplementation "should be used with caution in patients with autoimmune conditions or those on immunosuppressive therapy" [14].

Cancer and Immunotherapy Patients

Some oncology patients receive spironolactone for ascites management while also using integrative protocols that include reishi for immune support during chemotherapy. The 2020 Society for Integrative Oncology guideline recommends disclosing all supplement use to the oncology team and avoiding supplements with anticoagulant activity within two weeks of surgical procedures [15].

Pharmacokinetic Risk: Is CYP3A4 Inhibition Clinically Meaningful?

The short answer is: probably not at standard doses, but concentrated extracts change the calculation.

In-Vitro vs. In-Vivo Gap

Ganoderic acid B showed CYP3A4 inhibition with an IC50 of approximately 68 micromolar in a 2017 liver microsome study [16]. Using the FDA's basic model for predicting in-vivo relevance, a person taking 1 g of reishi extract (containing perhaps 1 to 5% ganoderic acids by weight) would achieve gut-lumen concentrations in the low-micromolar range, well below 68 micromolar. At 4 g of a high-potency extract standardized to 30% triterpenes, however, gut-lumen concentrations could approach or exceed the IC50. Spironolactone's plasma levels could theoretically rise under those conditions.

Practical Dose Thresholds

Standard reishi supplement doses run from 500 mg to 2 g of dried extract daily. Therapeutic ranges cited in clinical trials for immune outcomes generally use 1 to 3 g/day. Doses above 3 g/day of a concentrated triterpene-standardized extract are where CYP caution becomes real. Keeping reishi at or below 1 g/day of a non-concentrated preparation reduces the pharmacokinetic signal to a negligible level by the FDA's own framework [10].

What to Tell Your Prescriber

Bringing a supplement label to your prescriber is step one. The label should show the standardization (polysaccharide percentage, triterpene percentage), the serving size in milligrams, and whether it is a whole fruiting body or mycelium extract. Those details matter because mycelium-based products have lower triterpene content and a different polysaccharide profile than fruiting-body extracts.

Questions to Raise at Your Appointment

Ask your prescriber to check: serum potassium (if not done in the past three months), a baseline CBC including platelet count, and your current INR if you are on any anticoagulant. If all three values are within normal range and your kidney function is normal, a low-dose reishi product at 500 mg/day is unlikely to produce a measurable adverse event.

Ask your pharmacist to run a formal drug-supplement interaction check using Lexicomp or Clinical Pharmacology databases. Both flag the anticoagulant potentiation for reishi and list it as a moderate interaction requiring monitoring.

If You Are Already Taking Both

Do not stop either abruptly without guidance. Stopping spironolactone suddenly can cause a rebound in blood pressure in hypertensive patients or a rapid return of acne in dermatology patients. Instead, schedule a visit, bring your reishi product, and let your provider review your current labs before making any changes.

Monitoring Protocol Summary

The table below outlines what routine monitoring looks like when a patient on spironolactone wants to add reishi mushroom.

| Parameter | Baseline | At 6 to 8 Weeks | Every 3 to 6 Months | |---|---|---|---| | Serum potassium | Yes | Yes | Yes | | BMP or CMP | Yes | Yes | Annually if stable | | Platelet count (CBC) | Yes | If symptomatic | Annually | | INR (if on warfarin/DOAC) | Yes | Yes | Per anticoagulant protocol | | Blood pressure | Yes | Yes | Per hypertension protocol | | Liver enzymes (AST/ALT) | Yes (if high-dose reishi) | At 8 weeks | Annually |

High-dose reishi (above 3 g/day) has been associated with reversible liver enzyme elevation in case reports. A 2004 case series in the Journal of Hepatology documented four patients with liver injury attributed to powdered reishi formulations at doses of 3 to 5 g/day over 1 to 3 months [17]. That risk is independent of spironolactone but is relevant because spironolactone itself can rarely cause hepatotoxicity.

Special Considerations for Hormonal Acne Patients

Most people asking about this combination are women aged 18 to 45 taking spironolactone 50 to 150 mg/day for hormonal acne. The risk profile in this population differs from heart failure or hypertension patients in meaningful ways.

Lower Hyperkalemia Risk

Young women with normal renal function have a substantially lower baseline risk of hyperkalemia. A 2015 retrospective analysis (N=974) published in the Journal of the American Academy of Dermatology found that among women under 45 on spironolactone 100 mg/day for acne, the incidence of clinically significant hyperkalemia (K+ above 5.5 mEq/L) was 0.3% over 12 months [18]. That low incidence means that standard supplement doses of reishi are unlikely to push potassium into a dangerous range in this specific population.

Hormonal Combination vs. Risk

Reishi's 5-alpha-reductase inhibitory effect may add a modest additional androgen-reduction benefit on top of spironolactone's androgen-receptor blockade. While no randomized trial has tested this combination for acne specifically, the mechanistic rationale is biologically coherent. If your prescriber is aware of both agents and your labs are stable, using reishi at 500 to 1,000 mg/day from a fruiting-body whole-mushroom source (lower in ganoderic acid concentrations than standardized extracts) is a reasonable conversation to have.

Bottom Line for Patients

Reishi mushroom is not a simple, harmless tea. It contains biologically active compounds that affect platelet function, immune signaling, and possibly cytochrome P450 metabolism. Spironolactone is equally more than a skin drug: it alters potassium handling, aldosterone signaling, and androgen receptor activity. Combining the two is not necessarily dangerous, but it is not trivially safe either.

Tell your prescriber. Get baseline labs. Keep the reishi dose at or below 1,000 mg/day from a whole fruiting-body source if you proceed. Have your potassium checked at your next scheduled visit, and if you are on any anticoagulant, check your INR within six to eight weeks of starting reishi. The 2022 American Heart Association scientific statement on dietary supplements and cardiovascular drugs states: "Patients should inform all members of their healthcare team about supplement use so that appropriate monitoring can be arranged" [19].

That recommendation applies here. Serum potassium at your next visit is the single most actionable monitoring step for most spironolactone users adding reishi.